Literature DB >> 7103624

Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.

R A Kyle, R D Wagoner, K E Holley.   

Abstract

We describe two patients with primary systemic amyloidosis (AL) and the nephrotic syndrome. The administration of melphalan and prednisone was associated with resolution of the nephrotic syndrome. The serum albumin level returned to normal, proteinuria decreased to near normal, edema resolved, and the monoclonal protein in the serum and urine disappeared. In both patients, renal function remained stable and hepatomegaly disappeared. In both, however, amyloid deposition was greater in follow-up renal tissue than in the initial specimen. The effect of systemic therapy in AL must be assessed with histologic observations as well as clinical indexes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7103624     DOI: 10.1001/archinte.142.8.1445

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  19 in total

1.  Duodenal perforation in primary systemic amyloidosis.

Authors:  A G Fraser; G I Nicholson
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  Cytotoxic drugs for non-neoplastic disease.

Authors:  J M Whitehouse
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-09

3.  Presentations of primary amyloidosis.

Authors:  P A McCormick; D P O'Donoghue
Journal:  Ir J Med Sci       Date:  1985-12       Impact factor: 1.568

4.  Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins.

Authors:  Raymond Q Migrino; Seth Truran; David D Gutterman; Daniel A Franco; Megan Bright; Brittany Schlundt; Mitchell Timmons; Angelica Motta; Shane A Phillips; Parameswaran Hari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-30       Impact factor: 4.733

5.  Systemic and microvascular oxidative stress induced by light chain amyloidosis.

Authors:  Raymond Q Migrino; Parameswaran Hari; David D Gutterman; Megan Bright; Seth Truran; Brittany Schlundt; Shane A Phillips
Journal:  Int J Cardiol       Date:  2009-05-15       Impact factor: 4.164

6.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; A P Maxwell; I Bruce; B G Murphy; C C Doherty
Journal:  Ir J Med Sci       Date:  1993-06       Impact factor: 1.568

7.  A case of prominent hepatic cholestasis developing to hepatic failure in lambda-AL amyloidosis.

Authors:  K Dohmen; M Nagano; R Iwakiri; Y Yamano; Y Kikuchi; M Mizoguchi; Y Iwata; Y Mori; H Ishibashi
Journal:  Gastroenterol Jpn       Date:  1991-06

8.  Amyloid myopathy and myeloma: response to treatment.

Authors:  R A Sheehan-Dare; A V Simmons
Journal:  Postgrad Med J       Date:  1987-02       Impact factor: 2.401

Review 9.  Renal replacement therapy in multiple myeloma and systemic amyloidosis.

Authors:  J H Brown; C C Doherty
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

Review 10.  New advances in renal amyloidosis.

Authors:  Shinichi Nishi; Bassam Alchi; Nofumi Imai; Fumitake Gejyo
Journal:  Clin Exp Nephrol       Date:  2008-01-05       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.